Catalog No.
PHF75601
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human HPCA (Gly2-Phe193).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Neuron-specific calcium-binding protein hippocalcin, BDR2, HPCA, Calcium-binding protein BDR-2
Purification
Purified by antigen affinity column.
Accession
P84074
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial., PMID:39528049
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial., PMID:38129136
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial., PMID:37315583
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy., PMID:37156482
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study., PMID:35902297
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer., PMID:34955159
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial., PMID:34952708
Taking therapeutic apheresis services to patients in South Africa: An eight year review of SANBS mobile therapeutic apheresis service, 2013-2020., PMID:34116933
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study., PMID:33188992
Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus., PMID:33169707
Heparin-induced thrombocytopenia associated with collection of hematopoietic progenitor cells by apheresis., PMID:31696530
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer., PMID:29777975
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results., PMID:29045659
Optimization of the immunomagnetic selection in microcythemic donors enrolled for haploidentical transplantation., PMID:23433824
Cell processing for haplo-identical hematopoietic stem cell transplantation: automated washing and immunomagnetic-positive selection., PMID:22506843
Characterization of a Novel Monoclonal Antibody (27H2) Recognizing Human CD34 Class III Epitope., PMID:21286385
Electronic volume of CD34 positive cells from peripheral blood apheresis samples., PMID:18383271
Cellular volume and marker expression in human peripheral blood apheresis stem cells., PMID:18189285
Chimeric protein for selective cell attachment onto cellulosic substrates., PMID:17430973
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors., PMID:16740036
Use of a novel enzyme immunoassay based on detection of circulating antigen in serum for diagnosis of Helicobacter pylori infection., PMID:15242956
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines., PMID:12861049
Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines., PMID:12631625
The phenotype of Hurthle and Warthin-like papillary thyroid carcinomas is distinct from classic papillary carcinoma as to the expression of retinoblastoma protein and E2F-1 transcription factor., PMID:12610352
IL-10/IL-10 receptor signaling regulates TIMP-1 expression in primary human prostate tumor lines., PMID:12496489
Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens., PMID:12136252
Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1., PMID:11798512
[Expression of AC133 vs. CD34 in acute childhood leukemias]., PMID:10916777
Assessment of distribution of CD34 epitope classes in fresh and cryopreserved peripheral blood progenitor cells and acute myeloid leukemic blasts., PMID:10553156
An immunohistochemical study of basal cell carcinoma and trichoepithelioma., PMID:10446773
Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion., PMID:9918218
Expression of CD34-antigen in nasopharyngeal angiofibromas., PMID:9780070
Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry., PMID:9548262
Quality assurance of CD34+ cell estimation in leucapheresis products., PMID:8899197
BIRMA-K3, a new monoclonal antibody for CD34 immunophenotyping and stem and progenitor cell assay., PMID:8817393
Isolation and characterization of two monoclonal antibodies that recognize different epitopes of the human c-kit receptor., PMID:8727700
Storage of peripheral blood stem cell samples alters flow cytometric CD34+ results., PMID:8865943
Immunostaining for CD31 and CD34 in Kaposi sarcoma., PMID:8543622
Solitary fibrous tumors of soft tissue. A clinicopathologic and immunohistochemical study of 12 cases., PMID:7573687
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis., PMID:7563203
Hippocalcin in rat retina. Comparison with calbindin-D28k, calretinin and neurocalcin., PMID:7789406
Report from a Nordic workshop on CD34+ cell analysis: technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories., PMID:7538862
On the discriminatory value of anti-HPCA-1 (CD-34) in the differential diagnosis of benign and malignant cutaneous vascular proliferations., PMID:7526723
CD34 staining pattern distinguishes basal cell carcinoma from trichoepithelioma., PMID:7513986
High efficiency retroviral-mediated gene transduction into CD34+ cells purified from peripheral blood of breast cancer patients primed with chemotherapy and granulocyte-macrophage colony-stimulating factor., PMID:7514449
CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors., PMID:7511457
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product., PMID:7692921
Oral traumatic granuloma. Characterization of the cellular infiltrate., PMID:8100057
CD34 expression fails to predict the outcome in adult acute myeloid leukemia., PMID:7690733
Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue., PMID:7681857
For research use only. Not for human or drug use.
